HuGE Literature Finder
Records
1
-
16
| Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma. Cancer medicine 2022 Mar . Imaya Masayuki, Muramatsu Hideki, Narita Atsushi, Yamamori Ayako, Wakamatsu Manabu, Yoshida Taro, Miwata Shunsuke, Narita Kotaro, Ichikawa Daisuke, Hamada Motoharu, Nishikawa Eri, Kawashima Nozomu, Nishio Nobuhiro, Kojima Seiji, Takahashi Yoshiyu |
| Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 10 38 (36): 4231-4239. Zhu Ji, Liu Anwen, Sun Xinchen, Liu Luying, Zhu Yaqun, Zhang Tao, Jia Jianhui, Tan Shisheng, Wu Junxin, Wang Xin, Zhou Juying, Yang Jialin, Zhang Chen, Zhang Hongyan, Zhao Yuanyuan, Cai Gang, Zhang Wei, Xia Fan, Wan Juefeng, Zhang Hui, Shen Lijun, Cai SanJun, Zhang Zh |
| Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX. Cancer science 2019 Feb 110 (2): 707-716. Shirasu Hiromichi, Todaka Akiko, Omae Katsuhiro, Fujii Hirofumi, Mizuno Nobumasa, Ozaka Masato, Ueno Hideki, Kobayashi Satoshi, Uesugi Kazuhiro, Kobayashi Noritoshi, Hayashi Hideyuki, Sudo Kentaro, Okano Naohiro, Horita Yosuke, Kamei Keiko, Yukisawa Seigo, Kobayashi Marina, Fukutomi Aki |
| Distribution of uridine diphosphate glucuronosyltransferase 1A polymorphisms and their role in irinotecan-induced toxicity in patients with cancer. Oncology letters 2017 Nov 14 (5): 5743-5752. Wang Yang, Yi Cuihua, Wang Yawei, Li Hui, Li Bei, Wang Dan, Du Jintong, Liu Lian, Wang Xiuw |
| A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101). International journal of clinical oncology 2017 Oct 22 (5): 913-920. Ando Koji, Emi Yasunori, Suenaga Toyokuni, Hamanoue Masahiro, Maekawa Soichiro, Sakamoto Yasuo, Kai Seiichiro, Satake Hironaga, Shimose Takayuki, Shimokawa Mototsugu, Saeki Hiroshi, Oki Eiji, Sakai Kenji, Akagi Yoshito, Baba Hideo, Maehara Yoshihiko, |
| Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan-related toxicities in patients with lung cancer. Thoracic cancer 2017 Oct . Fukuda Minoru, Okumura Manabu, Iwakiri Tomomi, Arimori Kazuhiko, Honda Takuya, Kobayashi Kazuma, Senju Hiroaki, Takemoto Shinnosuke, Ikeda Takaya, Yamaguchi Hiroyuki, Nakatomi Katsumi, Matsuo Nobuko, Mukae Hiroshi, Ashizawa Kazu |
| Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A). Thoracic cancer 2017 Jan 8 (1): 40-45. Fukuda Minoru, Shimada Midori, Kitazaki Takeshi, Nagashima Seiji, Hashiguchi Kohji, Ebi Noriyuki, Takayama Koichi, Nakanishi Yoichi, Semba Hiroshi, Harada Taishi, Seto Takashi, Okamoto Isamu, Ichinose Yukito, Sugio Ken |
| Prospective study of the UGT1A1*27 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B). Thoracic cancer 2016 Jul 7 (4): 467-72. Fukuda Minoru, Suetsugu Takayuki, Shimada Midori, Kitazaki Takeshi, Hashiguchi Kohji, Kishimoto Junji, Harada Taishi, Seto Takashi, Ebi Noriyuki, Takayama Koichi, Sugio Kenji, Semba Hiroshi, Nakanishi Yoichi, Ichinose Yuki |
| Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer. Breast cancer (Tokyo, Japan) 2015 Jul 22 (4): 335-42. Otsuka Hiroko, Fujii Teruhiko, Toh Uhi, Iwakuma Nobutaka, Takahashi Ryuji, Mishima Mai, Takenaka Miki, Kakuma Tatsuyuki, Tanaka Maki, Shirouzu Kaz |
| [Association of UGT1A1 (*28, *60 and * 93) polymorphism with the adverse reactions of irinotecan chemotherapy in extensive stage small cell lung cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 2015 Jan 37 (1): 29-32. Ma Lixia, Chen Yan, Yang Changliang, Jiang Hui, Zhu Jing, Cheng Yi |
| Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011 Apr 22 (4): 890-6. Park S R, Kong S-Y, Rhee J, Park Y-I, Ryu K W, Lee J H, Kim Y-W, Choi I J, Kim C G, Lee J Y, Cho S-J, Kim N |
| UGT1A1 haplotype mutation among Asians in Singapore. Neonatology 2009 Mar 96 (3): 3. Zhou YY, Lee LY, Ng SY, Hia CP, Low KT, Chong YS, Goh DL |
| Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2008 Mar 17 (3): 695-701. Lankisch Tim O, Schulz Christoph, Zwingers Thomas, Erichsen Thomas J, Manns Michael P, Heinemann Volker, Strassburg Christian |
| Clinical pharmacogenetics of irinotecan (CPT-11). Drug metabolism reviews 2005 37 (3): 565-74. Ando Yuichi, Hasegawa Yoshino |
| Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan. Therapeutic drug monitoring 2002 1 24 (1): 111-6. Ando Yuichi, Ueoka Hiroshi, Sugiyama Toru, Ichiki Masao, Shimokata Kaoru, Hasegawa Yoshino |
| Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer research 2000 Dec 60 (24): 6921-6. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 28, 2023
- Content source: